MedTrace Logo

Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis

NCT07246759 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-11-24

No results posted yet for this study

Summary

The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit. The study analyzes Ly6Ehi neutrophils in biological samples from patients treated with immune checkpoint inhibitors to evaluate their likelihood of benefiting from treatment. Blood samples are collected prior to treatment and used to support the ongoing development of the algorithm.

Conditions

  • Non Small Cell Lung Cancer (NSCLC)
  • Melanoma (Skin Cancer)
  • Triple Negative Breast Cancer (TNBC)
  • RCC, Renal Cell Cancer
  • HNSCC

Interventions

OTHER

Blood sample collection

Blood sample collection prior treatment initiation

Sponsors & Collaborators

  • European Institute of Oncology

    collaborator OTHER

  • University Hospital Heidelberg

    collaborator OTHER

  • Hospital Universitario Virgen Macarena

    collaborator OTHER

  • OncoHost Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-15
Primary Completion
2027-09-30
Completion
2028-05-30

Countries

  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07246759 on ClinicalTrials.gov